Financial Data and Key Metrics Changes - Q4 revenue reached $5.9 billion, an increase of 7% and 3.9% organic growth, while full-year revenue was a record $21.8 billion, up 7.7% and 2.9% organic [4][5] - Adjusted diluted EPS for Q4 was $3.96, and for the full year, it was $14.40, representing a 9.6% growth, including a two-point impact from tariffs [5][18] - Adjusted gross margin for Q4 was 54.2%, and adjusted operating margin was 25.8%, with a 140 basis point impact from tariffs [17][18] Business Line Data and Key Metrics Changes - New BD segment showed strong organic growth of 4.9%, with double-digit growth in advanced patient monitoring and high single-digit growth in BD Interventional [4][6][7] - In pharma systems, biologics grew high single digits, driven by GLP-1s, while vaccine demand saw a decline [8][15] - Biosciences and diagnostic solutions returned to positive growth, with a significant recovery in BD BACTEC utilization [16][17] Market Data and Key Metrics Changes - Research funding in the biosciences business remained subdued, but sales in the U.S. and EMEA improved sequentially [6][16] - The China market is expected to decline in the mid-teens due to government policies, impacting growth by about 100 basis points [24][49] - Vaccines, which account for approximately 20% of pharma systems revenue, are expected to decline by about 25%, impacting growth by about 50 basis points [24] Company Strategy and Development Direction - The company is focused on accelerating its strategy as it transitions into new BD, emphasizing commercial excellence and innovation [9][10] - A two-year $200 million cost-out program has been initiated to address stranded corporate costs [12] - The company plans to enhance its capital allocation strategy, prioritizing internal investment, share repurchases, and a reliable dividend [21][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering mid-single digit revenue growth over the long term, despite transitory market dynamics [9][29] - The company is taking a prudent approach to guidance, incorporating updated views on the operating environment, particularly regarding vaccines and China [33][34] - Management highlighted the importance of BD Excellence in driving margin expansion and cash generation [20][63] Other Important Information - The company announced its 54th consecutive year of dividend increases and returned $2.2 billion to shareholders, including a $1 billion share buyback [5] - The Waters transaction is expected to unlock significant strategic and financial opportunities, with a projected close around the end of Q1 2026 [19][28] Q&A Session Summary Question: How does the guidance for new BD reflect conservatism? - Management emphasized a prudent approach to guidance, incorporating macro dynamics and not assuming improvements in the operating environment [32][33] Question: What are the expectations for Q1 compared to the full year? - Q1 guidance reflects full-year headwinds, with expectations for growth to step up in Q2 and Q3 [36][37] Question: Why not be more aggressive in returning capital to shareholders? - Management stated a focus on cash generation and disciplined capital allocation, with plans for significant share buybacks post-Waters transaction [40][41] Question: What is the expected impact of Alaris on fiscal 2026? - Alaris is expected to be a headwind of over 100 basis points in fiscal 2026, with a strong contribution in fiscal 2025 [56][58] Question: How will the company drive operating margin expansion? - Management highlighted the role of BD Excellence in driving gross margin improvement and operational efficiency [63][65]

Core Viewpoint - Medical device maker Becton Dickinson exceeded Wall Street estimates for fourth-quarter adjusted profit and provided a forecast for 2026 earnings that is slightly above expectations, driven by steady demand for its products [1] Financial Performance - Becton Dickinson reported fourth-quarter adjusted profit that surpassed Wall Street estimates, indicating strong financial performance [1] - The company’s earnings forecast for 2026 is slightly above expectations, suggesting confidence in future growth [1] Market Demand - Steady demand for Becton Dickinson's products has been a key factor supporting its financial results and outlook [1]

Core Insights - Becton Dickinson (BDX) reported quarterly earnings of $3.96 per share, exceeding the Zacks Consensus Estimate of $3.92 per share, and showing an increase from $3.81 per share a year ago, representing an earnings surprise of +1.02% [1] - The company achieved revenues of $5.89 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.04% and up from $5.44 billion year-over-year [2] - Becton Dickinson has outperformed consensus EPS estimates in all four quarters over the past year, while it has topped revenue estimates three times in the same period [2] Earnings Outlook - The future performance of Becton Dickinson's stock will largely depend on management's commentary during the earnings call and the sustainability of its immediate price movement based on the latest earnings numbers and future expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $3.25 on revenues of $5.39 billion, and for the current fiscal year, it is $14.79 on revenues of $22.77 billion [7] Industry Context - The Medical - Dental Supplies industry, to which Becton Dickinson belongs, is currently ranked in the top 17% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The correlation between near-term stock movements and earnings estimate revisions suggests that tracking these revisions can provide insights into potential stock performance [5]

Financial Performance - FY25 revenue reached $21.84 billion, with adjusted FXN growth of 7.7% and organic growth of 2.9%[16,44] - Adjusted diluted EPS for FY25 was $14.40, a 9.6% year-over-year increase[16] - Adjusted operating margin for FY25 was 25.0%, an increase of 80 bps year-over-year[16] - The company returned $2.2 billion to shareholders through share repurchases and dividends[16,48] - Free cash flow for FY25 was $2.67 billion, a 14% decrease compared to FY24's $3.119 billion[47] Segment Performance (Q4 FY25) - BD Medical segment revenue was $3.155 billion, with a 9.9% FXN increase[34] - BD Life Sciences segment revenue was $1.368 billion, with a 0.3% FXN increase[36] - BD Interventional segment revenue was $1.367 billion, with a 7.5% FXN increase[39] FY26 Guidance - The company expects low single-digit revenue growth (FXN) for FY26, including a ~90 bps FX tailwind[53] - Adjusted diluted EPS for FY26 is projected to be between $14.75 and $15.05, a 2.4% to 4.5% increase[53]

Core Insights - BD reported a resilient business model with a 3.9% organic growth in fiscal 2025, alongside significant adjusted margin and earnings growth [2] - The company is on track to complete the combination of its Biosciences and Diagnostic Solutions business with Waters Corporation by the end of Q1 2026, aiming to enhance its position in the Med Tech industry [2] Financial Performance - Q4 2025 revenues reached $5.89 billion, marking an 8.3% increase year-over-year, with a 3.9% organic growth [4][6] - For FY 2025, total revenues were $21.84 billion, up 8.2% from FY 2024, with adjusted diluted EPS growing by 9.6% to $14.40 [6][27] - Q4 GAAP diluted EPS increased to $1.72, a 24.6% rise compared to the previous year [6][27] Segment Performance - BD Medical segment revenues grew by 11.2% to $3.16 billion, driven by strong performance in Advanced Patient Monitoring [9][32] - BD Life Sciences segment saw a modest growth of 2.1% to $1.37 billion, with Specimen Management showing solid performance [11][32] - BD Interventional segment revenues increased by 8.5% to $1.37 billion, with notable growth in Urology and Critical Care [12][32] Geographic Results - In the United States, revenues increased by 9.8% to $3.42 billion, while international revenues grew by 6.4% to $2.47 billion [5][32] - The U.S. market showed strong growth across various segments, particularly in Medication Delivery Solutions and Advanced Patient Monitoring [30][31] Future Outlook - The company provided guidance for FY 2026, expecting low single-digit revenue growth and adjusted diluted EPS in the range of $14.75 to $15.05 [13][14] - The outlook reflects various assumptions about market conditions and operational performance [13]

Core Points - BD (Becton, Dickinson and Company) has declared a quarterly dividend of $1.05 per common share, marking a 1.0% increase from the previous quarter, with an annual dividend rate of $4.20 per share for fiscal year 2026 [1][2] - This marks the 54th consecutive fiscal year that BD has raised its dividend, maintaining its status in the S&P 500 Dividend Aristocrats Index, which tracks companies with at least 25 consecutive years of dividend increases [2] - The increase in dividends reflects BD's confidence in its long-term outlook and commitment to returning capital to shareholders, even while executing the Waters RMT transaction [2] Company Overview - BD is one of the largest global medical technology companies, focused on improving medical discovery, diagnostics, and care delivery [2] - The company employs over 70,000 individuals and is dedicated to enhancing the safety and efficiency of healthcare delivery, supporting laboratory scientists, and advancing research capabilities [2] - BD collaborates with organizations worldwide to tackle significant global health challenges, aiming to improve outcomes, lower costs, and expand access to healthcare [2]

Core Insights - The eighth China International Import Expo (CIIE) showcased several innovative medical devices and healthcare products, attracting significant attention from global trade delegations [1][2] Group 1: Medical Devices - Boston Scientific presented the ENROUTE Transcarotid Artery Revascularization (TCAR) device, the first and only approved device for TCAR procedures, aimed at reducing intraoperative risks associated with carotid artery stenosis [1] - Another product from Boston Scientific, the FARAWAVE NAV catheter, utilizes non-thermal electric fields for cardiac tissue ablation and has treated approximately 500,000 patients globally [1] - Medtronic introduced the Inceptiv closed-loop rechargeable spinal nerve stimulation system, designed to improve the quality of life for patients with chronic pain through weak electrical stimulation [4] - BD Medical showcased the M.R.I™ 4F Slim Implantable Port, the thinnest catheter in its category, designed for the Chinese population, which significantly reduces thrombosis rates by 40% [4] - The Venclose™ catheter, designed for treating lower limb varicose veins, features a flexible setup that minimizes patient trauma [5] Group 2: Innovative Treatments - Fosun Pharma presented the Exablate Neuro system, a high-intensity focused ultrasound (HIFU) device combined with MRI for treating drug-resistant essential tremors and Parkinson's disease [6] - Eli Lilly introduced innovative drugs targeting aging and obesity, including donanemab for Alzheimer's disease, which has shown to delay disease progression by approximately 30% in clinical trials [6]

Core Insights - BD has achieved full enrollment of the iliac artery patient cohort in its AGILITY study, which evaluates the Revello™ Vascular Covered Stent for treating peripheral arterial disease (PAD) [1][4] - The AGILITY study is a multi-center, prospective study being conducted across 45 investigational sites in the U.S., Europe, Australia, and New Zealand [4] - PAD affects over 21 million Americans and more than 200 million people globally, highlighting the critical need for innovative treatment options [5] Company Overview - BD is a leading global medical technology company focused on improving medical discovery, diagnostics, and care delivery [6] - The company employs over 70,000 individuals and collaborates with organizations worldwide to tackle significant global health challenges [6] Study Details - The AGILITY study aims to assess the safety and effectiveness of the Revello™ Vascular Covered Stent for de novo or restenotic lesions in two patient cohorts: the common and external iliac artery cohort (n=118) and the superficial femoral and proximal popliteal artery cohort (n=223) [7] - The study represents a significant advancement in self-expanding covered stent technology, addressing the need for improved flexibility and deliverability in PAD treatment [3][4]

Core Insights - BD (Becton, Dickinson and Company) has received FDA 510(k) clearance and CE marking for its Enteric Bacterial Panel (EBP) and Enteric Bacterial Panel plus (EBP plus) for the BD COR™ System, enhancing diagnostic capabilities for gastrointestinal infections [1][2]. Group 1: Product Features and Benefits - The EBP and EBP plus utilize advanced Polymerase Chain Reaction (PCR) technology to test a wide range of gastrointestinal bacterial pathogens from a single stool swab, streamlining workflows for clinicians [1][2]. - The EBP plus is the only high-throughput, bacterial-only molecular panel that detects Enterotoxigenic Escherichia coli (ETEC) and associated toxins, improving patient management and reducing unnecessary antibiotic use [3]. - The BD COR™ System can automate nearly 1,650 tests and deliver up to 1,000 sample results in 24 hours, maximizing efficiency with minimal manual interaction [4]. Group 2: Market Context and Impact - Gastrointestinal infections lead to over 1.7 million deaths globally each year, with significant healthcare burdens in the U.S., including 179 million outpatient visits and 500,000 hospitalizations annually due to diarrhea [1]. - The introduction of these panels addresses the urgent need for rapid and accurate diagnostics, which is critical for improving patient outcomes and supporting antimicrobial stewardship [1][2]. Group 3: Company Overview - BD is one of the largest global medical technology companies, focused on advancing health through innovative technology and solutions that enhance clinical therapy and healthcare delivery [7][8]. - The company has a strong commitment to improving the safety and efficiency of healthcare processes, with a presence in virtually every country and partnerships aimed at addressing global health challenges [8].

Core Insights - Dividend Aristocrats are considered some of the best stocks to purchase during market downturns due to their strong financial foundations [1] Group 1 - Dividend Aristocrats are backed by companies with solid footing, making them reliable investment options [1]